Vervain

Metadata

Approved Indications

Commission E

• No monograph — Vervain was not assessed by the German Commission E

ESCOP

• No monograph — Not included in ESCOP monograph collection

EMA/HMPC

• Traditional use: Herbal medicinal product used as an expectorant in cough associated with cold
• Traditional use: Herbal medicinal product for the relief of mild pain associated with menstrual periods
• Based on long-standing traditional use (at least 30 years, including 15 years within the EU)

Agreement/Disagreement Between Bodies

The absence of Commission E and ESCOP monographs is notable and reflects the limited clinical evidence base for vervain as a monotherapy. Only EMA/HMPC has issued a traditional use monograph, and this is the lowest tier of regulatory recognition — acknowledging long-standing traditional use without requiring clinical trial evidence. The most important modern therapeutic context for vervain is its inclusion in Sinupret, where its contribution is supported by the combination product’s clinical evidence rather than vervain-specific studies.

Conditions Treated

Primary

• Cough associated with common cold (expectorant, traditional use)
• Component of Sinupret for acute rhinosinusitis

Secondary

• Mild menstrual pain (EMA traditional use)

Traditional/Historical

• Fever and feverish conditions
• Nervous exhaustion and anxiety
• Digestive complaints
• Wound healing (topical, historical)
• Inflammation of the mouth and throat (gargle)
• In folk medicine, vervain was considered a near-universal remedy (“Wundkraut”) and held considerable ritual and magical significance in pre-modern European cultures

Mechanism of Action

Key Active Constituents

• Iridoid glycosides: Verbenalin (cornin), hastatoside — primary marker compounds
• Phenylethanoid glycosides: Verbascoside (acteoside) — major phenolic compound with anti-inflammatory and antioxidant activity
• Flavonoids: Apigenin, luteolin, and their glycosides
• Essential oil: Present only in trace amounts (unlike lemon verbena, Aloysia citriodora)
• Phenolic acids: Caffeic acid derivatives

Proposed Mechanisms

1. Anti-inflammatory Activity

   • Verbascoside inhibits NF-kB activation and reduces pro-inflammatory cytokine production (in vitro)
   • Iridoid glycosides contribute to anti-inflammatory effects
   • Relevance to both respiratory and menstrual indications

2. Secretolytic/Expectorant Effect

   • Verbenalin and hastatoside are believed to promote bronchial secretion and mucociliary clearance
   • Contributes to the secretolytic profile of Sinupret

3. Mild Analgesic Activity

   • Iridoid glycosides may contribute to mild pain-relieving effects
   • Proposed basis for the EMA menstrual pain indication, though evidence is limited to traditional use reports

4. Antioxidant Activity

   • Verbascoside is a potent antioxidant in vitro (comparable to or exceeding vitamin C and Trolox in DPPH assays)
   • Clinical significance of this antioxidant activity is unclear

5. In Sinupret Combination

   • Contributes anti-inflammatory and secretolytic properties
   • Part of a 5-herb combination (with gentian root, elderflower, primrose, and sorrel) that has demonstrated clinical efficacy in acute rhinosinusitis

Pharmacokinetics

• Limited data on isolated vervain
• Verbenalin is hydrolyzed in the gut to the aglycone
• Verbascoside is partially absorbed and undergoes extensive first-pass metabolism

Clinical Evidence Summary

Vervain Monotherapy

• No published randomized controlled trials for vervain monotherapy have been identified
• The EMA traditional use monograph is based entirely on long-standing use and pharmacological plausibility, not clinical trial data
• Some preclinical (in vitro and animal) studies support anti-inflammatory and analgesic properties, but these have not been confirmed in human trials

As Component of Sinupret (BNO 1016)

• Vervain is one of five herbs in Sinupret (with gentian, elderflower, primrose, and sorrel)
• Sinupret has robust clinical evidence for acute rhinosinusitis (see Primrose Cowslip for detailed combination evidence)
• The specific contribution of vervain to Sinupret’s efficacy cannot be isolated from the combination

Preclinical Evidence

• Verbascoside: Demonstrated anti-inflammatory effects in multiple in vitro models (NF-kB inhibition, COX-2 suppression)
• Verbenalin: Showed analgesic effects in animal models (acetic acid writhing test)
• Whole extract: Anti-inflammatory activity in carrageenan-induced paw edema model (animal)

Evidence Limitations

• Complete absence of human clinical trial evidence for monotherapy
• Traditional use is the sole basis for regulatory status
• Preclinical data is promising but insufficient to establish clinical efficacy
• Evidence rating E is appropriate: traditional use only, with no modern clinical substantiation for monotherapy

European vs. US/Anglophone Consensus

Safety Profile

Contraindications

• Known hypersensitivity to Verbena officinalis or other Verbenaceae family members
• No other specific contraindications documented

Drug Interactions

• No clinically significant drug interactions documented
• Theoretical interactions are not substantiated
• The low potency and limited clinical use make interaction data scarce rather than reassuring

Side Effects

• Very rare: Mild GI disturbances (nausea, diarrhea) reported occasionally
• Rare: Allergic skin reactions (contact dermatitis)
• Overall: No significant adverse effects reported in the literature at recommended doses

Pregnancy/Lactation

• Pregnancy: EMA does NOT recommend use during pregnancy due to insufficient safety data. Traditional texts suggest vervain may stimulate uterine contractions (uterotonic effect), though this is poorly documented. Avoid as a precaution.
• Lactation: Not recommended due to insufficient safety data
• No formal reproductive toxicity studies identified

Clinical Dosage

Recommended Forms and Doses

As Sinupret Component

• Dosing is per the Sinupret combination product (see Primrose Cowslip)
• Sinupret contains vervain herb alongside gentian root, elderflower, primrose, and sorrel

Duration of Treatment

• For cough/cold: 1-2 weeks (self-limiting condition)
• For menstrual pain: During symptomatic period
• Consult a physician if symptoms persist beyond 1 week or worsen

Sources

• EMA/HMPC. Community herbal monograph on Verbena officinalis L., herba. European Medicines Agency, 2010.
• EMA/HMPC. Assessment report on Verbena officinalis L., herba. European Medicines Agency.
• Deepak M, Handa SS. Antiinflammatory activity and chemical composition of extracts of Verbena officinalis. Phytother Res. 2000;14(6):463-465.
• Speroni E et al. Sedative effects of crude extract of Verbena officinalis. Fitoterapia. 1996;67(3):257-261.
• Rehecho S et al. Ethnopharmacology of Verbena officinalis. J Ethnopharmacol. 2011;136(3):382-391.
• Alipieva K et al. Verbascoside — a review of its occurrence, (bio)synthesis and pharmacological significance. Biotechnol Adv. 2014;32(6):1065-1076.
• Koch E, Biber A. Treatment of rats with the Sinupret dry extract BNO 1016 enhances ciliary beat frequency in organ cultures of mouse tracheal epithelium. Phytomedicine. 2008;15:876-882.

Connections

• Component of Sinupret — see Primrose Cowslip for combination evidence
• Compare respiratory use with Elderflower (also a Sinupret component and traditional cold remedy)
• Compare expectorant role with Thyme (stronger evidence base for cough/bronchitis)
• Compare respiratory approach with Pelargonium Sidoides (direct antiviral mechanism vs. traditional secretolytic)